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Abstract
The prevalence of heart failure in Europe and worldwide is high. This syndrome is a common cause of
hospitalization and has a significant impact on morbidity, mortality and healthcare costs in highly developed
countries. The study of biomarkers in heart failure is of wide interest as they can improve diagnosis, predict the
development of heart failure and its decompensation, and help in assessing treatment outcomes.
The objective of the research was to study the feasibility of using multiple biomarker strategy for diagnosing
decompensated heart failure in the post-infarction period and to assess changes in these markers after treatment
with succinic acid and arginine preparations.
Materials and Methods. There were examined 120 patients with Q-QS wave and non-Q wave myocardial
infarction complicated by decompensated heart failure. All the patients were divided into 2 groups (depending on
Q-QS wave and non-Q wave myocardial infarction) and 4 subgroups (depending on rehabilitation therapy) being
homogenous by age and gender.
Results. When studying the dynamics of changes in blood level of N-terminal pro-B-type brain natriuretic
peptide and ST2, there was observed its significant reduction in all the patients with prior Q-QS wave myocardial
infarction complicated by decompensated heart failure after treatment. The most significant changes were
observed in the patients of Group IV who, on the background of basic therapy, received succinic acid and arginine
preparations according to the proposed scheme. The combined use of arginine preparations and succinic acid in
combination therapy for decompensated heart failure secondary to prior Q-QS wave myocardial infarction allowed
reducing blood levels of N-terminal pro-B-type brain natriuretic peptide under conditions of graded exercises.
Similar tendencies were observed when determining this indicator in the patients with non-Q wave myocardial
infarction complicated by decompensated heart failure after rehabilitation treatment.
Conclusions. The use of succinic acid and arginine preparations when treating the patients with prior Q-
QS wave and non-Q wave myocardial infarction complicated by decompensated heart failure allowed us to
significantly reduce the level of immunological enzymes such as N-terminal pro-B-type brain natriuretic peptide
and ST2, which indicate the presence and development of decompensated heart failure after myocardial
infarction.
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Problem statement and analysis of
the latest research
According to the European Society of Cardiology
(ESC), heart failure (HF) is defined as a clinical
syndrome characterized by typical symptoms (e.g.
shortness of breath, swollen and tired calf muscles)
that are accompanied by the signs (e.g. elevated
jugular venous pressure, peripheral oedema of the
lower extremities) resulted from structural and/or
functional cardiac changes due to a reduced cardiac
output and elevated intra-cardiac pressure at rest or
during exercise [7]. Since human life expectancy
has increased, the incidence of HF and its decom-
pensation has increased as well, resulting in signifi-
cant costs to the healthcare system [6]. Decompen-
sated HF accounts for 1, 110, 000 hospitalizations
annually causing 60, 000 deaths worldwide which
costs to local budgets > 39 billion per year [1]. A
significant proportion (< 40%) of these patients
have HF with reduced ejection fraction (EF), while
the rest are diagnosed with HF with preserved and
mid-range left ventricular (LV) EF [14]. Despite
years of clinical research, cardiac biomarkers have
been accepted as those used for routine assessment
of cardiovascular diseases. According to current
ESC guidelines, troponin and natriuretic peptides
are preferred biomarkers, while amongst the most
promising newer biomarkers, growth stimulation
expressed gene 2 (ST2) has emerged as a promis-
ing one. These biomarkers are extremely valuable;
however, none of them can be used independently,
without the clinical context [2].
Natriuretic peptides, especially B-type brain na-
triuretic peptide (BNP) and its precursor N-terminal
pro-B-type brain natriuretic peptide (NT-proBNP),
are currently widely used in clinical practice and
their measurement is recommended by the ESC as a
part of diagnosis and management of HF [7]. Both
BNP and NT-proBNP are very accurate and useful
when diagnosing decompensated HF, as well as us-
ing them in routine clinical practice [8]. Despite
an important role of these peptides when managing
the patients with HF, the use of natriuretic peptides
has certain limitations. Their increase is typical for
valvular HF, pulmonary hypotension, pulmonary
embolism, atrial fibrillation and sepsis as well [9].
ST2 is a member of the interleukin-1 (IL-1) su-
perfamily, that binds to IL-33 and is a cytokine
which is mainly secreted by cardiac fibroblasts in
response to cell damage [3]. ST2 is a powerful pre-
dictive biomarker for HF both during stabilization
and decompensation [4, 5] with two main isoforms:
transmembrane receptor (ST2L) and soluble recep-
tor (sST2) [10]. Effects of IL-33 such as its increase
in response to myocardial stress, cardioprotective
effect, reduction in myocardial fibrosis, prevention
of cardiomyocyte hypertrophy and apoptosis, are
manifested precisely by the ST2L receptor and are
blocked when IL-33 binds to the sST2L receptor,
that occurs when sST2L levels increase. This ex-
plains why sST2L levels increase in remodeling, hy-
pertrophy in the patients with HF, especially in case
of its development after prior myocardial infarction
(MI) [3]. It is worth saying that the concentration
of sST2 increases in bronchial asthma, rheumatoid
arthritis, systemic lupus erythematosus and sepsis
as well [11]. SST2 closely correlates with LV EF,
disease severity, post-infarction LV remodeling; it
is a predictor of pulmonary hypertension, right ven-
tricular hypokinesis and jugular vein distension in
acute decompensated HF [12]. Dieplinger et al. re-
ported, that in healthy Austrian population, mean
ST2 levels in men were 4-31 ng/ml and mean ST2
levels in women were 2-21 ng/ml [18, 19], while,
despite the same methods of the analysis, in healthy
American population, these indicators were as fol-
lows: 8.6-49.3 ng/ml and 7.2-33.5 ng/ml, respec-
tively [20]. The MERLIN-TIMI-36 data showed
that value of 35 ng/ml was acceptable; however, it
is not conclusively known whether gender-based
thresholds should be considered [13].
The results of the multiple-marker ProBNP Out-
patient Tailored Chronic Heart Failure Therapy (PRO-
TECT) sub-study of 151 patients with New York
Heart Association (NYHA) functional class (FC) II
to IV systolic HF (LVEF ≤ 40%) indicated that the
measurements of ST2, growth differentiation factor
15 (GDF-15) and high-sensitive troponin (hsTrop)
provided an independent prognostic value [17]. In
2003, Weinberg et al. recorded that short-term
changes in sST2 levels were prognostically valu-
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able in diagnosing mortality or heart transplantation
regardless of NT-proBNP levels in the patients with
HF [21].
Over the past four decades, treatment of the
patients with LV systolic dysfunction has changed
from digoxin and diuretics to a number of thera-
peutic strategies targeted to the main pathophysio-
logical mechanisms of developing HF and its de-
compensation, including the effect on myocardial
contractibility, vasodilation, inhibition of neurohu-
moral activation and anti-inflammatory pathways
[15]. Modern treatment of the patients with HF and
reduced LV EF after MI is based on the use of beta-
blockers, angiotensin-converting-enzyme inhibitors,
mineralocorticoid receptor antagonists [16]. As the
heart is one of the most highly energy consuming
organs, adjuvant therapy, that is aimed at increasing
energetic metabolism, possesses cytoprotective and
adaptive effects, reduces endothelial dysfunction
and has a great potential [25]. Several preparations
with antioxidant, anti-inflammatory, antiplatelet and
hypolipidemic properties are known [24]. Among
the groups of such preparations, succinic acid de-
serves special attention. Succinate, a salt or ester
of succinic acid, is an important intermediate in
the tricarboxylic acid cycle. In mitochondria, it
plays a crucial role in generating adenosine triphos-
phate. Over recent years, it has been widely used
in immunology and oncology [22, 23]. Endothe-
lial dysfunction is an important pathophysiological
mechanism of developing HF and its decompensa-
tion, including disruption of the nitric oxide (NO)
pathway [26]. The L-arginine-NO pathway is a
complex system that affects vasomotor tone, cell
adhesion, platelet aggregation, cell proliferation and
angiogenesis [27]. Therefore, the use of arginine
preparations in this group of the patients requires
further study.
The objective of the research was to study
the feasibility of using multiple biomarker strat-
egy for diagnosing decompensated HF in the post-
infarction period and to assess changes in these
markers after treatment with succinic acid and argi-
nine preparations.
1. Materials and Methods
There were examined 120 patients with Q-QS wave
and non-Q wave MI, stage II A-B decompensated
chronic HF according to the classification proposed
by Vasylenko V.Kh. and Strazhesko M.D., NYHA
FC III-IV. The patients with Q-QS wave MI (60
individuals) were divided into 4 groups depend-
ing on the treatment method: Group I comprised
15 patients who received basic therapy in accor-
dance with the protocols of the Ministry of Health
of Ukraine (lisinopril - 10 mg once a day; biso-
prolol fumarate - 10 mg once a day; eplerenone -
50 mg once a day; valsartan - 40 mg twice a day;
ivabradine - 5 mg twice a day); Group 2 included
15 patients who, on the background of basic ther-
apy, received a preparation of succinic acid accord-
ing to the proposed scheme; Group 3 included 15
patients who, on the background of basic therapy,
received arginine preparations according to the pro-
posed scheme; Group 4 comprised 15 patients who,
on the background of basic therapy, received suc-
cinic acid and arginine preparations according to the
proposed scheme. The patients with non-Q wave
MI (60 individuals) were divided into 4 analogous
groups. Tivortin - arginine hydrochloride manu-
factured by Yuria-Pharm, Kyiv, Ukraine; approved
by the Order of the Ministry of Health of Ukraine
of September 18, 2008 No 528, registration num-
ber UA/8954/01/01. An intravenous infusion of
4.5% Tivortin solution was administered at a dose
of 100 ml once a day at a drip rate of 10 drops per
minute within the first 10-15 minutes by increasing
drip rate to 30 drops per minute (within the first
10 days). Tivortin aspartate - L-arginine aspartate,
aspartic acid manufactured by Yuria-Pharm, Kyiv,
Ukraine; approved by the Order of the Ministry
of Health of Ukraine of July 18, 2009, registra-
tion number UA/9941/01/01. The preparation was
administered orally at a dose of 5 ml 5 times per
day with a meal (the maximum daily dose is 8 g)
since the 11th day of randomization for 15 days.
Mexicor - 3-hydroxy-6-methyl-2-ethylpyridine suc-
cinate, solution for injections manufactured by LLC
”Ekofarminvest”, Russian Federation; approved by
the Order of the Ministry of Health of Ukraine of
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July 18, 2006, registration number UA/4971/01/01.
The solution diluted in either sodium chloride or
5% dextrose in water was infused slowly at a dose
of 100-150 ml for 30-90 minutes 3 times per day
every 8 hours within the first 10 days. The rec-
ommended daily therapeutic dose is 6-9 mg; the
maximum single dose is 2 mg/kg of body weight.
The maximum daily dose should not exceed 800
mg; the maximum single dose is 250 mg. Mexicor -
ethyl-methyl-hydroxypyridine succinate, capsules
manufactured by LLC ”Ekofarminvest”, Russian
Federation; approved by the Order of the Ministry
of Health of Ukraine of March 06, 2015, registra-
tion number UA/4971/02/01. The preparation was
administered orally at a dose of 100 mg 3 times
per day since the 10th day of hospitalization for 5
months. The maximum therapeutic dose is 800 mg;
the maximum single dose is 200 mg. The daily
dose was divided into 3 doses given during the day.
The patients were observed on the 1st day of hos-
pitalization and within the 1st and 2nd months after
outpatient treatment.
Study groups were homogenous by age, gender,
disease severity, duration of the post-infarction pe-
riod, clinical signs of decompensation, that served
as a basis for inclusion of the patients in the study.
Serum concentrations of NT-proBNP, ST2 were
measured before treatment, 1 month and 2 months
after treatment. All the patients underwent the six-
minute walk test (6 MWT).
2. Results and Discussion
When studying the dynamics of changes in blood
level of NT-proBNP, there was observed its signif-
icant reduction in all the patients with prior Q-QS
wave MI complicated by decompensated HF after
treatment (Table 1).
Thus, in the patients, who received basic ther-
apy, the concentration of NT-proBNP reduced grad-
ually from (948.33±2.99) pg/ml at the beginning of
treatment to (780.33±3.18) pg/ml and
(710.33±2.89) pg/ml 1 and 2 months after the be-
ginning of therapy, respectively (p<0.05), consti-
tuting 17.71% and 25.15% of the initial values.
In the patients, who received succinic acid, there
was observed a similar reduction in blood levels
of NT-proBNP (by 26.38% and 29.09%) – from
(951.27±3.10) pg/ml before treatment to
(700.33±3.44) pg/ml and (674.53±2.61) pg/ml 1
and 2 months after the beginning of treatment, re-
spectively (p<0.05). In the patients of Group III,
the level of NT-proBNP was (952.00±2.33) pg/ml
at the beginning of treatment and reduced by 21.27%
and 24.26% - to (749.53±3.60) pg/ml, and 2
(721.07±2.84) pg/ml (p<0.05). The combined use
of arginine preparations and succinic acid, when
treating the patients with Q-QS wave MI and de-
compensated HF, allowed reducing blood levels of
NT-proBNP by 41.03% 2 months after the begin-
ning of treatment. In this group, the level of NT-
proBNP was (949.73±3.67) pg/ml before treatment,
(620.07±3.43) pg/ml 1 month after the beginning
of treatment and (560.07±3.10) pg/ml 2 months
after the beginning of treatment (p<0.05).
The analysis of the dynamics of changes in NT-
proBNP level during graded exercises showed the
differences in the effect of treatment on the dynam-
ics of changes in the indicators. Thus, in the pa-
tients, who received basic therapy during all the ob-
servation periods, the level of NT-proBNP reduced
gradually by 9.25% and 20.75% 1 and 2 months
after the beginning of treatment, respectively, that
was significantly lower as compared to the patients
before exercising. In the patients, who received
succinic acid, the level of NT-proBNP reduced by
18.68% and 27.16% constituting
(1045.53±2.28) pg/ml before treatment,
(850.20±3.14) pg/ml and (761.53±2.88) pg/ml af-
ter the beginning of treatment (p<0.05). There was
no significant difference in the dynamics of changes
in NT-proBNP levels after graded exercises in the
patients, who, on the background of basic therapy,
received arginine preparations. Thus, before treat-
ment, NT-proBNP level was (1049.00±2.48) pg/ml,
while 1 and 2 months after the beginning of treat-
ment, it was (919.33±3.15) pg/ml and
(800.53±3.16) pg/ml, respectively (p<0.05). The
combined use of arginine preparations and succinic
acid in combination therapy for decompensated HF
secondary to prior Q-QS wave MI allowed reducing
blood levels of NT-proBNP under conditions of
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Table 1. Dynamics of changes in NT-proBNP indicators in the patients with decompensated HF after Q-QS wave MI during the course of
treatment.
Group of patients
Standard treatment
Standard treatment +
succinic acid
Standard treatment +
arginine preparations
Standard treatment +
succinic acid + arginine
preparations
(n=15) (n=15) (n=15) (n=15)
Complaints
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
NT-proBNP,
pg/ml, before
exercises
948.33
±2.99
780.33
±3.18
710.33
±2.89 951.27±3.10
700.33
±3.44
674.53
±2.61 952.00±2.33
749.53
±3.60
721.07
±2.84 949.73±3.67
620.07
±3.43
560.07
±3.10
p1*
p1*,
p2*
p1*
p1*,
p2*
p1*
p1*,
p2*
p1*
p1*,
p2*
∆1, % - -17.71 -25.15 - -26.38 -29.09 - -21.27 -24.26 - -34.71 -41.03
NT-proBNP,
pg/ml, after
exercises
1047.60
±5.18
950.20
±2.86
830.27
±3.10 1045.53±2.28
850.20
±3.14
761.53
±2.88 1049.00±2.48
919.33
±3.15
800.53
±3.16 1046.13±2.92
730.00
±2.90
609.80
±3.12
p1*
p1*,
p2*
p1*
p1*,
p2*
p1*
p1*,
p2*
p1*
p1*,
p2*
∆1, % - -9.25 -20.75 - -18.68 -27.16 - -12.34 -23.69 - -30.22 -41.71
∆2, % 10.47 21.77 16.88 9.9 21.39 8.73 10.18 22.65 11.02 10.15 17.72 8.87
Notes:
1. the reliability of difference scores p1 – as compared to the indicators before treatment; p2 – as compared to the indicators 1 month after
the beginning of treatment; * – p<0.05, ** – p>0.05.
2. ∆1 – the increase or reduction (-) in the indicator during the course of treatment as a percentage to the values before treatment.
3. ∆2 – the increase or reduction (-) in the indicator during the course of treatment as percentage depending on physical exercises.
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Table 2. Dynamics of changes in NT-proBNP indicators in the patients with decompensated HF after non-Q wave MI during the course of
treatment.
Group of patients
Standard treatment
Standard treatment +
succinic acid
Standard treatment +
arginine preparations
Standard treatment +
succinic acid + arginine
preparations
(n=15) (n=15) (n=15) (n=15)
Complaints
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
NT-proBNP,
pg/ml, before
exercises
951.40
±2.59
770.00
±2.98
705.80
±2.93 950.27±3.28
694.60
±2.87
670.60
±3.22 948.87±3.46
734.33
±3.27
714.80
±2.93 951.13±2.28
610.40
±2.85
555.40
±2.75
p1*
p1*,
p2*
p1*
p1*,
p2*
p1*
p1*,
p2*
p1*
p1*,
p2*
∆1, % - -19.07 -25.81 - -26.9 -29.43 - -22.61 -24.67 - -35.82 -41.61
NT-proBNP,
pg/ml, after
exercises
1050.00
±3.38
919.73
±3.24
810.00
±3.51 1048.87±3.16
811.20
±3.17
730.27
±3.53 1048.40±2.38
900.47
±3.02
790.53
±3.07 1048.93±3.43
706.67
±3.02
602.33
±3.29
p1*
p1*,
p2*
p1*
p1*,
p2*
p1*
p1*,
p2*
p1*
p1*,
p2*
∆1, % - -12.41 -22.86 - -22.66 -30.38 - -14.11 -24.68 - -32.63 -42.58
∆2, % 10.36 19.45 14.76 10.38 11.68 8.89 10.49 10.59 9.57 10.28 15.77 8.45
Notes:
1. the reliability of difference scores p1 – as compared to the indicators before treatment; p2 – as compared to the indicators 1 month after
the beginning of treatment; * – p<0.05, ** – p>0.05.
2. ∆1 – the increase or reduction (-) in the indicator during the course of treatment as a percentage to the values before treatment.
3. ∆2 – the increase or reduction (-) in the indicator during the course of treatment as a percentage depending on physical exercises.
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graded exercises. In this group of the patients, the
level of NT-proBNP was (1046.13±2.92) pg/ml be-
fore treatment and reduced to (730.00±2.90) pg/ml
and (609.80±3.12) pg/ml (p<0.05).
The analysis of the dynamics of changes in
blood level of NT-proBNP showed its significant
reduction during a 2-month observation period in
all the patients (Table 2).
Thus, in the patients, who received standard
therapy, the concentration of NT-proBNP reduced
from (951.40±2.59) pg/ml at the beginning of treat-
ment to (770.00±2.98) pg/ml and
(705.80±2.93) pg/ml 1 and 2 months after the be-
ginning of treatment (p<0.05). In the patients treated
with succinic acid, the level of NT-proBNP was
(950.27±3.28) pg/ml and reduced significantly by
29.60% and 29.43% after treatment -
(694.60±2.87) pg/ml and (670.60±3.22) pg/ml, re-
spectively (p<0.05). In the patients who, on the
background of basic therapy, received arginine prepa-
rations, the level of NT-proBNP was
(948.87±3.46) pg/ml before treatment, and reduced
to (714.80±2.93) pg/ml after treatment (p<0.05).
The combined use of arginine preparations and suc-
cinic acid on the background of standard therapy for
non-Q wave MI and decompensated HF contributed
to the reduction in blood levels of NT-proBNP by
35.82% and 41.61% 1 and 2 months after the be-
ginning of treatment. In this group, the level of NT-
proBNP was (951.13±2.28) pg/ml at the beginning
of treatment, (610.40±2.85) pg/ml 1 month after
the beginning of treatment and (555.40±2.75) pg/ml
2 months after the beginning of treatment (p<0.05).
The study of changes in NT-proBNP concentra-
tion during graded exercises showed certain differ-
ences in the effect of proposed schemata of therapy
on changes in the indicators. Thus, in the patients
with decompensated HF, who received standard
therapy, the level of NT-proBNP reduced by 12.41%
and 22.86% 1 and 2 months after the beginning of
treatment, respectively, that was significantly lower
as compared to the patients before exercising.
In the patients, who received succinic acid, the
level of NT-proBNP reduced by 22.66% and 30.38%
1 and 2 months after the beginning of treatment, con-
stituting (811.20±3.17) pg/ml and
(730.27±3.53) pg/ml, respectively (p<0.05). There
was no significant difference in the dynamics of
changes in NT-proBNP levels in the patients, who
received arginine preparations. The level of NT-
proBNP was (1048.40±2.38) pg/ml and reduced
by 24.68% to (790.53±3.07) pg/ml after 2 months
of treatment (p<0.05). In combined use of the
proposed preparations on the background of stan-
dard therapy, the average value of this indicator was
(1048.93±3.43) pg/ml before treatment, whereas
1 and 2 months after the beginning of treatment, it
was (706.67±3.02) pg/ml and (602.33±3.29) pg/ml,
respectively (p<0.05).
According to the data presented in Table 3, all
the proposed schemata of therapy led to a signifi-
cant reduction in serum level of this peptide after the
end of treatment. In the patients of Group I, who re-
ceived basic therapy, the median ST2 concentration
before treatment was (49.47±1.77) ng/ml, while 1
and 2 months after the beginning of treatment, it
was (44.92±1.22) ng/ml and (41.67±1.18) ng/ml,
respectively (p<0.05). When succinic acid was
added to basic therapy, the level of this indicator
before treatment was (49.00±1.25) ng/ml reducing
significantly by 22.31% and 26.67% 1 and 2 months
after the beginning of treatment to
(38.07±2.28) ng/ml and (35.93±1.79) ng/ml
(p<0.05). In the patients of Group III, who, on
the background of basic therapy, received arginine
preparations, the level of ST2 after 2 months of
treatment was (37.07±1.91) ng/ml, that was sig-
nificantly lower (by 22.98%) as compared to that
before therapy - (48.13±0.99) ng/ml (p<0.05). In
the patients of Group IV, the concentration of ST2
before treatment was (49.40±1.12) ng/ml, signif-
icantly reducing by 28.80% and 41.30% 1 month
and especially 2 months after the beginning of treat-
ment with succinic acid and arginine preparations
to (35.13±2.47) ng/ml and (29.00±2.98) ng/ml, re-
spectively (p<0.05).
The effect of treatment in the patients with prior
non-Q wave MI complicated by decompensated HF
was analyzed.
According to the data presented in Table 4, in
the patients, who received basic therapy, serum level
of ST2 was (48.93±1.83) ng/ml reducing signifi-
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Table 3. Dynamics of changes in ST2 indicators in the patients with decompensated HF after Q-QS wave MI during the course of treatment.
Group of patients
Standard treatment
Standard treatment +
succinic acid
Standard treatment +
arginine preparations
Standard treatment +
succinic acid + arginine
preparations
(n=15) (n=15) (n=15) (n=15)
Complaints
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
ST2, ng/ml
49.47
±1.77
44.92
±1.22
41.67
±1.18
49.00
±1.25
38.07
±2.28
3593
±1.79 48.13±0.99
42.13
±2.61
37.07
±1.91 49.40±1.12
35.13
±2.47
29.00
±2.98
p* p*, p1* p* p* p*, p1* p* p*, p1* p* p*, p1*
∆, % -9.19 -15.77 -22.31 -26.67 -12.47 -22.98 -28.8 -41.3
Notes:
1. the reliability of difference scores p – as compared to the indicators before treatment; p1 – as compared to the indicators 1 month after
the beginning of treatment; * – p<0.05, ** – p>0.05.
2. ∆ – the increase or reduction (-) in the indicator during the course of treatment as a percentage to the values before treatment.
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Table 4. Dynamics of changes in ST2 indicators in the patients with HF after non-Q wave MI during the course of treatment.
Group of patients
Standard treatment
Standard treatment +
succinic acid
Standard treatment +
arginine preparations
Standard treatment +
succinic acid + arginine
preparations
(n=15) (n=15) (n=15) (n=15)
Complaints
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
Before
treat-
ment
1
month
2
months
ST2
ST2, 48.93
±1.83
43.33
±1.80
40.07
±2.43 48.80±3.32
37.13
±1.92
34.13
±2.03 48.93±2.43
39.80
±2.86
36.07
±2.25 48.53±3.93
32.93
±2.12
28.00
±2.39
p* p*, p1* p* p*, p1* p* p*, p1*
∆, % -11.45 -18.11 -23.91 -30.06 -18.66 -26.28 -32.15 -42.3
Notes:
1. the reliability of difference scores p – as compared to the indicators before treatment; p1 – as compared to the indicators 1 month after
the beginning of treatment; * – p<0.05, ** – p>0.05.
2. ∆ – the increase or reduction (-) in the indicator during the course of treatment as a percentage to the values before treatment.
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cantly by 18.11% to (40.07±2.43) ng/ml (p<0.05)
after the end of treatment. There was observed
a reduction in serum level of ST2 in the patients,
who received succinic acid on the background of
standard therapy as well. In this group, the indi-
cator was (48.80±3.32) ng/ml before treatment,
and (37.13±1.92) ng/ml and (34.13±2.03) ng/ml
1 and 2 months after the beginning of treatment,
respectively (p<0.05). In the patients of Group
III, serum level of ST2 was (48.93±2.43) ng/ml
before treatment; 1 and 2 months after the begin-
ning of treatment, it was (39.80±2.86) ng/ml and
(36.07±2.25) ng/ml, respectively (p<0.05) that was
18.66% and 26.28% lower as compared to the initial
data. In the patients of Group IV, serum concentra-
tion of ST2 before treatment was
(48.53±3.93) ng/ml, significantly reducing by
32.15% and 42.30% 1 and 2 months after the be-
ginning of treatment to (32.93±2.12) ng/ml and
(28.00±2.39) ng/ml, respectively (p<0.05).
Thus, the use in patients after QQS and non-Q
MI, complicated by decompensated HF, succinic
acid and arginine preparations, can significantly re-
duce the level of immunological enzymes, which
indicate the presence and development of cardiac
decompensation. Thus, it was proved that the ad-
dition of these drugs to the base therapy was ac-
companied by the most pronounced decrease in the
levels of ST2 and NT-proBNP both at rest and after
exercise (p<0.05).
3. Prospects of Further
Researches
Since the determination of serum concentration of
NTproBNP and ST2 in the patients with decompen-
sated HF secondary to MI is promising when ana-
lyzing treatment outcomes, further study of using
multiple-marker quality assessment and individual
treatment perception is required.
4. Conclusions
Natriuretic peptides are currently widely used in
daily clinical practice not only in case of a large
number of hospitalized patients with decompen-
sated HF as confirmed by clinical trials. The issue
of multiple biomarker strategy for HF therapy in the
early and late post-infarction period is an extremely
important and promising part of further research in
this field.
The introduction of ST2 into routine practice,
alongside with the use of NT-proBNP, will signifi-
cantly reduce hospital costs by reducing the number
of re-hospitalizations, canceling or replacing inac-
tive drugs and improve quality of life in the patients
with decompensated HF.
The use of succinic acid and arginine prepa-
rations, and especially their combination on the
background of basic therapy, will significantly re-
duce serum concentration of NT-proBNP and ST2
in such patients, that, surely, confirms their positive
therapeutic effect.
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